The Eurotransbio consortium Re.Mark.RareDis led by Minoryx, Rare Partners and CISI, has been selected for receiving funds to investigate on drug repositioning in rare diseases
2013-01-07
Drug repositioning as a strategy to find new cures for rare diseases.
The Eurotransbio consortium Re.Mark.RareDis led by Minoryx, Rare Partners and CISI, has been selected for receiving funds to investigate on rare diseases.
The consortium aims to combine chemical technologies and predictive experimental models to identify new treatments against rare diseases.
Composed by Spanish and Italian companies, the consortium explores the potential for repositioning of known drugs and clinical candidates in seven rare diseases, throughgh a network of collaborators in academy.
view pdf